Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité- Universitätsmedizin, Berlin, Germany.
J Dtsch Dermatol Ges. 2011 Oct;9 Suppl 6:S1-57. doi: 10.1111/j.1610-0379.2011.07802.x.
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.
雄激素性脱发是最常见的脱发疾病，影响男性和女性。雄激素性脱发的最初迹象通常在青少年时期出现，导致进行性脱发和模式分布。此外，其频率随年龄增长而增加，影响高达 80%的白种男性和 42%的女性。诊断为雄激素性脱发的患者可能会经历生活质量的显著受损。尽管患病率高，并且有多种治疗选择，但迄今为止，男性和女性雄激素性脱发的治疗还没有国家或国际循证指南。因此，欧洲皮肤病学会（EDF）启动了一个项目，制定雄激素性脱发治疗的循证 S3 指南。基于系统的文献研究，评估了目前可用治疗方法的疗效，并在共识会议上通过了治疗建议。本指南的目的是为皮肤科医生和全科医生提供一种循证工具，以便为雄激素性脱发患者选择一种有效且安全的治疗方法。
